Get the Stockscreener App
29.02
1.53%
-0.45
Arcutis Biotherapeutics Inc stock is traded at $29.02, with a volume of 1.73M.
It is down -1.53% in the last 24 hours and up +23.75% over the past month.
Arcutis Biotherapeutics Inc is a medical dermatology company. It is developing treatments for patients with immune-mediated dermatological diseases and conditions. It is leveraging recent advances in immunology and inflammation to develop differentiated therapies against biologically validated targets to solve persistent treatment challenges in serious diseases of the skin. The company's product candidate ZORYVE roflumilast cream, has completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population.
See More
Previous Close:
$29.47
Open:
$29.35
24h Volume:
1.73M
Relative Volume:
0.76
Market Cap:
$3.55B
Revenue:
$59.61M
Net Income/Loss:
$-262.14M
P/E Ratio:
-7.4031
EPS:
-3.92
Net Cash Flow:
$-247.49M
1W Performance:
-6.99%
1M Performance:
+23.75%
6M Performance:
+114.96%
1Y Performance:
+136.90%
1-Day Range:
$28.30
$29.50
1-Week Range:
$28.30
$31.77
52-Week Range:
$11.13
$31.77
Arcutis Biotherapeutics Inc Stock (ARQT) Company Profile
Name
Arcutis Biotherapeutics Inc
Sector
Industry
Phone
805-418-5006
Address
3027 TOWNSGATE ROAD, WESTLAKE VILLAGE, CA
Compare ARQT with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ARQT
Arcutis Biotherapeutics Inc
|
29.02 | 3.61B | 59.61M | -262.14M | -247.49M | -3.92 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.04 | 113.14B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
741.29 | 78.49B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
877.94 | 54.76B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
397.55 | 54.51B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
197.01 | 41.64B | 447.02M | -1.18B | -906.14M | -6.1812 |
Arcutis Biotherapeutics Inc Stock (ARQT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-25-25 | Initiated | Goldman | Neutral |
| Dec-30-24 | Initiated | H.C. Wainwright | Buy |
| Aug-28-24 | Initiated | Jefferies | Buy |
| Jan-03-24 | Upgrade | Mizuho | Neutral → Buy |
| Oct-26-23 | Downgrade | Mizuho | Buy → Neutral |
| Oct-13-23 | Downgrade | Goldman | Buy → Neutral |
| Sep-07-22 | Initiated | Needham | Buy |
| Mar-17-22 | Initiated | Goldman | Buy |
| Jun-30-21 | Initiated | Mizuho | Buy |
| May-27-21 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Nov-09-20 | Upgrade | Goldman | Neutral → Buy |
| Oct-08-20 | Initiated | Truist | Buy |
| Feb-25-20 | Initiated | Cantor Fitzgerald | Overweight |
| Feb-25-20 | Initiated | Cowen | Outperform |
| Feb-25-20 | Initiated | Goldman | Neutral |
| Feb-25-20 | Initiated | Guggenheim | Buy |
View All
Arcutis Biotherapeutics Inc Stock (ARQT) Latest News
Tori Spelling Teams Up with Arcutis to Share Her Family’s Eczema Journey - WKEF
Looking Into Arcutis Biotherapeutics Inc's Recent Short Interest - Benzinga
What Makes Arcutis Biotherapeutics, Inc. (ARQT) a Strong Momentum Stock: Buy Now? - sharewise.com
Stempoint Capital LP Sells 334,401 Shares of Arcutis Biotherapeutics, Inc. $ARQT - MarketBeat
Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Stock Rockets 28% As Investors Are Less Pessimistic Than Expected - simplywall.st
Arcutis Strengthens Board of Directors with New Appointment of Amit Munshi and Honors Retirement of Bhaskar Chaudhuri - BioSpace
Arcutis Biotherapeutics Appoints Amit Munshi as New Director - TipRanks
Amit Munshi joins Arcutis board as founder Chaudhuri retires - Investing.com
Arcutis Biotherapeutics Announces Board Changes - TradingView
Amit Munshi joins Arcutis board as founder Chaudhuri retires By Investing.com - Investing.com India
Arcutis strengthens board of directors with new appointment of Amit Munshi - marketscreener.com
Arcutis Strengthens Board of Directors with New Appointment - GlobeNewswire
Arcutis Biotherapeutics | 12/8/25 - Channel 13 Las Vegas News KTNV
Arcutis Biotherapeutics: The Earnings Inflection Has Arrived (ARQT) - Seeking Alpha
Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat
Arcutis Biotherapeutics Stock Jump Looks Great, But How Secure Is That Gain? - Trefis
XTX Topco Ltd Reduces Position in Arcutis Biotherapeutics, Inc. $ARQT - MarketBeat
Arcutis Biotherapeutics (NASDAQ:ARQT) Downgraded to "Buy" Rating by Wall Street Zen - MarketBeat
Arcutis Biotherapeutics (NASDAQ:ARQT) Reaches New 1-Year HighStill a Buy? - MarketBeat
What risks investors should watch in Arcutis Biotherapeutics Inc. stockRate Cut & Reliable Breakout Forecasts - Newser
Howard Welgus Sells 10,000 Shares of Arcutis Biotherapeutics (NASDAQ:ARQT) Stock - MarketBeat
Arcutis Biotherapeutics (NASDAQ:ARQT) Insider Sells 1,657 Shares - MarketBeat
Arcutis Biotherapeutics stock hits 52-week high at 31.29 USD - Investing.com
Arcutis Biotherapeutics stock hits 52-week high at 31.29 USD By Investing.com - Investing.com Canada
Insider Sell: Howard Welgus Sells 10,000 Shares of Arcutis Bioth - GuruFocus
Assessing Arcutis Biotherapeutics (ARQT) Valuation After Its Strong 1-Year Share Price Surge - Yahoo Finance
Arcutis Biotherapeutics Insider Sold Shares Worth $302,133, According to a Recent SEC Filing - marketscreener.com
AZN's Baxdrostat Gets FDA Priority Tag for Uncontrolled Hypertension - Finviz
Is the Options Market Predicting a Spike in Arcutis Biotherapeutics Stock? - sharewise.com
Arcutis Biotherapeutics: Behind The Big Rally (NASDAQ:ARQT) - Seeking Alpha
(ARQT) and the Role of Price-Sensitive Allocations - news.stocktradersdaily.com
American Century Companies Inc. Purchases 71,815 Shares of Arcutis Biotherapeutics, Inc. $ARQT - MarketBeat
Arcutis Biotherapeutics Inc (ARQT) Stock Price, Trades & News - GuruFocus
Arcutis Biotherapeutics, Inc. $ARQT is Tejara Capital Ltd's 2nd Largest Position - MarketBeat
Mizuho Maintains Arcutis Biotherapeutics (ARQT) Outperform Recommendation - Nasdaq
Mizuho raises Arcutis Biotherapeutics stock price target on strong Zoryve sales By Investing.com - Investing.com South Africa
Mizuho raises Arcutis Biotherapeutics stock price target on strong Zoryve sales - Investing.com Nigeria
Mizuho Raises Price Target on Arcutis Biotherapeutics (ARQT) to $37 | ARQT Stock News - GuruFocus
Geode Capital Management LLC Has $36.21 Million Stake in Arcutis Biotherapeutics, Inc. $ARQT - MarketBeat
Franklin Resources Inc. Sells 28,990 Shares of Arcutis Biotherapeutics, Inc. $ARQT - MarketBeat
DNB Asset Management AS Buys Shares of 28,171 Arcutis Biotherapeutics, Inc. $ARQT - MarketBeat
Arcutis Biotherapeutics Surges 112% in 2025 Is the Rally Justified After Regulatory Milestones? - Yahoo Finance
Arcutis Biotherapeutics stock reaches 52-week high at 31.1 USD By Investing.com - Investing.com Australia
Arcutis Biotherapeutics stock reaches 52-week high at 31.1 USD - Investing.com
Arcutis Biotherapeutics (ARQT) Is Up 12.6% After FDA Accepts ZORYVE sNDA for Pediatric Psoriasis Review - Yahoo Finance
Intech Investment Management LLC Has $1.21 Million Stock Position in Arcutis Biotherapeutics, Inc. $ARQT - MarketBeat
Why Shares in Arcutis Biotherapeutics Surged Again This Week - AOL.com
Arcutis Biotherapeutics director Lin sells $777,955 in shares By Investing.com - Investing.com UK
Arcutis Biotherapeutics director Lin sells $777,955 in shares - Investing.com
Arcutis Biotherapeutics Director Sells Shares - TradingView
Dir Lin Sells 25,272 ($778K) Of Arcutis Biotherapeutics Inc [ARQT] - TradingView
Arcutis Biotherapeutics Inc Stock (ARQT) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.08%
0.91%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):